CERC-007 is a fully human anti-IL-18 monoclonal antibody with the potential to address multiple auto-inflammatory diseases, including Adult Onset Still's Disease (AOSD) and Multiple Myeloma (MM). IL-18 is a pro-inflammatory cytokine; patients with AOSD and MM show elevated levels of IL-18. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in AOSD and MM patients in 2020


Targeting Adult Onset Still's Disease

Adult Onset Still's Disease - Adult onset Still's disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). Affected individuals may develop episodes of high, spiking fevers, a pink or salmon colored rash, joint pain, muscle pain, a sore throat and other symptoms associated with systemic inflammatory disease.

Multiple Myeloma - Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs.  Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications.

of CERC-007

  • Fully human, high affinity, neutralizing monoclonal antibody against IL-18
  • Evaluated in Phase 1 study; safe and well-tolerated up to 1000 mg with IL-18 knockdown out to 3 months following single dose
  • Potential for biomarker-driven clinical development approach for patient selection and dose titration